Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2023; 29(36): 5240-5253
Published online Sep 28, 2023. doi: 10.3748/wjg.v29.i36.5240
Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer
Ke Xu, Ai-Ru Yu, Shen-Bin Pan, Jie He
Ke Xu, Ai-Ru Yu, Shen-Bin Pan, Jie He, Clinical Medical College, Chengdu Medical College, Chengdu 610500, Sichuan Province, China
Ke Xu, Ai-Ru Yu, Shen-Bin Pan, Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan Province, China
Jie He, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan Province, China
Author contributions: He J conceived and designed the study; Xu K, He J, Yu AR, and Pan SB performed the collection and assembly of data; Xu K, He J, and Yu AR performed study quality evaluation; Xu K and He J performed data analysis and interpretation; Xu K and Pan SB wrote the initial draft; All authors revised the manuscript, read and approved the final version of the manuscript.
Supported by Natural Science Foundation of Sichuan Province, No. 2023NSFSC0729; Wu Jieping Foundation Special Fund for Clinical Research, No. 320.6750.2022-19-100; Foundation of Key Clinical Specialty of Sichuan Province, No. 2022; School Foundation of Chengdu Medical College, No. CYZYB21-05.
Conflict-of-interest statement: The authors deny any conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie He, PhD, Doctor, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, No. 278 Baoguang Street, Chengdu 610500, Sichuan Province, China. 2325@cmc.edu.cn
Received: June 20, 2023
Peer-review started: June 20, 2023
First decision: August 26, 2023
Revised: September 1, 2023
Accepted: September 7, 2023
Article in press: September 7, 2023
Published online: September 28, 2023
Processing time: 92 Days and 5.4 Hours
ARTICLE HIGHLIGHTS
Research background

Currently, DNA methylation is one of the most commonly used detection targets for circulating tumor DNA (ctDNA) in plasma, and is often explored as a diagnostic biomarker for cancer. The diagnostic value of combined methylated branched chain amino acid transaminase 1 (BCAT1)/IKAROS family zinc finger 1 (IKZF1) in plasma for colorectal cancer (CRC) has been explored since 2015. Recently, several related studies have published their results and showed its diagnostic efficacy.

Research motivation

To fully understand the diagnostic value of methylated BCAT1/IKZF1 in initial diagnosis and postoperative recurrence of CRC.

Research objectives

To evaluate the diagnostic accuracy of methylated BCAT1/IKZF1 in plasma for screening and postoperative follow-up of patients with CRC.

Research methods

We searched the PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases. Studies on the diagnostic accuracy of methylated BCAT1/IKZF1 in plasma for CRC were retrieved. Data extraction, pooled analysis, subgroup analysis, sensitivity analysis, and publication bias analysis were performed.

Research results

The pooled sensitivity and specificity of methylated BCAT1/IKZF1 for CRC diagnosis were 60% [95% confidence interval (CI) 53-67] and 92% (95%CI: 90-94), respectively. The positive likelihood ratio and negative likelihood ratio were 8.0 (95%CI: 5.8-11.0) and 0.43 (95%CI: 0.36-0.52), respectively. The diagnostic odds ratio and area under the curve were 19 (95%CI: 11-30) and 0.88 (95%CI: 0.85-0.91), respectively.

Research conclusions

The detection of methylated BCAT1/IKZF1 in plasma, as a non-invasive detection method of ctDNA, has potential in the diagnosis of CRC, but the clinical application value still needs to be explored.

Research perspectives

The detection of methylated BCAT1/IKZF1 in plasma, similar to other detection methods, has poor diagnostic sensitivity for early-stage disease, which may limit its clinical application in CRC screening. In the future, the clinical application of methylated BCAT1/IKZF1 in plasma can be promoted by combining it with other tests.